INNOVATE (VATE) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue declined 22.7% year-over-year to $242.0 million, mainly due to lower activity in Infrastructure and Spectrum, partially offset by strong Life Sciences growth.

• Net loss attributable to shareholders was $22.0 million ($1.67 per diluted share), compared to net income of $14.1 million ($1.03 per share) in Q2 2024, reflecting a significant year-over-year decline.

• Adjusted EBITDA fell to $15.7 million from $26.7 million year-over-year, driven by declines in Infrastructure and Spectrum, partially offset by Life Sciences.

• Significant refinancing transactions were completed post-quarter, extending debt maturities and improving financial flexibility.

• Substantial doubt exists about the ability to continue as a going concern due to upcoming debt maturities and cross-default provisions, though management is pursuing asset sales and refinancing.

Financial highlights

• Q2 2025 consolidated revenue: $242.0 million, down from $313.1 million in Q2 2024.

• Net loss: $22.0 million vs. net income of $14.1 million year-over-year.

• Adjusted EBITDA: $15.7 million, down from $26.7 million in Q2 2024.

• Cash and cash equivalents at June 30, 2025: $33.4 million, down from $48.8 million at year-end 2024.

• Gross profit for Q2 2025: $45.6 million, down from $65.6 million in Q2 2024.

Outlook and guidance

• Management is exploring asset sales, refinancing, and capital raising to address liquidity and debt maturities.

• Infrastructure segment aims to convert $1.3 billion backlog to revenue and add $400 million in new awards in Q3.

• Life Sciences is expected to benefit from recent regulatory approvals and strong R2 sales.

• Spectrum segment projects improvement in ad sales and new network launches in the second half of 2025, focusing on datacasting and 5G broadcast opportunities.

• Strategic alternatives for operating subsidiaries are being evaluated, with milestones required under new debt covenants.